<DOC>
	<DOCNO>NCT00466869</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , two-to three center study . The study consist 2 treatment group ( Betahistine 48 mg/day match placebo ) . Approximately 30 subject ( 15 per treatment group ) randomize 6-week study . A single blind placebo treat period 14 day use determine subject suitability inclusion trial . In order patient define valid inclusion study , patient able present consistent LDL-C value , take prior randomization ( screen visit 1 screen visit 2 ) , without deviation 12 % value mean . Within one week second screening visit , subject meet inclusion criterion none exclusion criterion randomly assign 1 follow treatment group : - Betahistine 24 mg BID ( 48 mg/day total ) , - Matching placebo BID . Double-blind treatment continue 4 week . Study medication ( betahistine and/or match placebo ) administer BID ( lunch dinner ) . During study , subject undergo dietary assessment . The primary efficacy parameter change LDL-C baseline ( randomization ) Week 4 percentage patient reduce LDL-C 10 % .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Examine Effect Betahistine Plasma Lipids Patients Treated With Simvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Signed write informed consent ; Male female subject 30 75 year age ; Treated Simvastatin ( Simovil , C500 , Simvacor , SimvastatinTeva , Simvaxon ) dose exceed 40 mg/day . Has stable ( unchanged ) dose Simvastatin least 3 month prior screen ; If female , nonlactating , negative urine pregnancy test result , plan become pregnant study , childbearing potential ( hysterectomy tubal ligation least 6 month prior randomization postmenopausal 1 year ) ; childbearing potential ( include perimenopausal woman menstrual period within one year ) must practice willing continue practice appropriate birth control ( implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire study duration Consistent LDLcholesterol value , take Visit 1 2 ( screen visit 1 screen visit 2 ) , without deviation 12 % value mean . Patients keep stable diet constant exercise activity last 3 month , per patient statement . Patients compliant ( take &gt; 80 % ) study medication screen period . Has uncontrolled hyperlipidemia ( triglycerides [ TG ] &gt; =300mg/dL lowdensity lipoprotein cholesterol [ LDLC ] &gt; 160 mg/dL &lt; 100mg/dL Has recently start plan start smoke cessation program ; Has BMI le 18.5 kg/m2 high 40 kg/m2 Has major change daily physical activity ( e.g. , initiation exercise program ) start weight loss program within 90 day prior screen ; Is unwilling unable participate dietary assessment part study ; Has clinically significant history presence follow condition : History myocardial infarction , cerebrovascular accident , stroke , unstable angina , percutaneous transluminal coronary angioplasty ( PTCA ) , coronary artery bypass graft ( CABG ) , cardiac valve abnormality require use anticoagulant SBE prophylaxis , within six month prior screen visit 1 . Congestive heart failure ( NYHA class 3 4 ) . Significant arrhythmia conduction disturbance ( e.g . : second third degree AV block without cardiac pacemaker , multiple multifocal ventricular ectopic beat ) . History pancreatitis and/or serum amylase &gt; 2xULN ) addition clinical sign pancreatitis . History gastrointestinal disease ( e.g . Crohn 's disease ) could result impaired absorption study drug . Type 1 diabetes mellitus ; Treated Type 2 diabetes mellitus ( metformin monotherapy and/or diet allow ) HbA1c &gt; 8 % ; Severe type 2 diabetes history ketoacidosis diabetic ulcer , presence retinopathy , neuropathy , nephropathy ; Renal insufficiency define serum creatinine &gt; =1.5 mg/dL ( 133 µmol/L ) screening ; Previous malignant disease within 5 year screen : ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 x ULN ; CPK ( creatine phosphokinase ) &gt; 3 x ULN Hypothyroid patient define : TSH &gt; 7.5 mU/l 5 &lt; TSH &lt; 7.5 mU/l total T4 &lt; 4.00 mcg/dl ( 51.5 nmol/l ) ( regardless patient replacement therapy ) . Plans surgery ( elective otherwise ) course study ; Has uncontrolled hypertension ( sit blood pressure &gt; 160/100 mmHg screen randomization ) . History asthma ; History peptic ulcer ; History HIV Any disease condition might preclude patient 's regular participation study ( e.g . endocrine disease , acute chronic infection , know suspected drug alcohol abuse psychiatric neurological disorder require chronic medication ( e.g. , antidepressant ) ; Chronic need use antihistamine ; Has stable treatment regimen follow medication minimum 90 day prior screen : Hormone replacement therapy ; Oral contraceptive ; Antihypertensive agent ; Metformin ; hyroid replacement therapy ; Has treat past 60 day , currently treat , expect require undergo treatment follow excluded medication : All prescription overthecounter agent take purpose treat dyslipidemia , include ( limit ) follow agent : Statins Rosuvastatin ( Crestor ) , Fluvastatin ( Lescol ) , Atorvastatin ( Lipitor , Torid ) , Pravastatin ( Pravalip , Pravastatin ) . Fibrates Bezafibrate ( Bezafibrate 400 Sr , Norlip ) Ciprofibrate Lipanor ) Bile acid sequestrant Colestipol ( Colestid ) Cholesterol absorption inhibitor Ezetimibe ( Ezetrol ) Nicotinic acid derivative Acipimox ( Olbetam ) Omega3acid Triomar , Omacor Overthecounter hypolipidemic agent ( e.g. , vitamin , herbal supplement alternative remedy ) ; All prescription overthecounter agent take purpose weight reduction , include ( limit ) follow anti obesity agent : Prescription drug orlistat ( Xenical® ) , sibutramine ( Reductil ) , phentermine ( Razin ) . Psychotropic/neurological agent include follow : Antipsychotic agent ( e.g. , Olanzapine , Clozapine , Risperidol , Lithium , etc. ) . Antiepileptic agent ( e.g. , Topamax® , Zonegran® , valproate , carbamazepine ) . Antidepressant agent include follow : monoamine oxidase inhibitor , bupropion ( Zyban® ) , tricyclic antidepressant , tetracyclic antidepressant ; selective serotonin reuptake inhibitor ( e.g. , Prozac® , Paxil® , Zoloft® , etc . ) ; Systemic steroid administer oral , intravenous , intramuscular route ; Drugs directly affect gastrointestinal motility ( e.g. , Reglan® Propulsid® , chronic [ take 10 day within 6month period prior screen visit 1 ] macrolide antibiotic erythromycin new derivative ) : Calcitonin ( e.g. , Miacalcin® ) ; Insulin ; αglucosidase inhibitor ( Prandase® ) ; Sulfonylureas ( e.g. , Amaryl® , Diabitex® , Glibetic® , Gluben® , Gluco Rite® Novonorm® Orsinon® ) ; Or Meglitinide ( e.g . NovoNorm ) Rosilitazone ( e.g . Avandamet ® Avandia® Rossini® ) Receipt investigational treatment ( drug device ) within 30 day prior screen ; Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site ; Is employ OBEcure Ltd .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>